drugset
drugset / Trial / NCT05396885

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

NCT05396885 ↗

Phase 2 Active not recruiting 136 enrolled Kite, A Gilead Company Arcellx, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.

Timeline

Start
2022-07-15
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anitocabtagene Autoleucel Cell therapy 1.15e+08 cells Intravenous

Indications

plasma cell myeloma